BIIB:US
$117.21
0.334%

Biogen Inc.
News & Events

Last updated: May 8, 2025, 3:50 AM ET

  1. Leqembi®? (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

    GlobeNewswire APR 15, 2025 7:00 PM EDT
    In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a cli...
    READ ARTICLE
  2. Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease

    GlobeNewswire APR 2, 2025 7:30 AM EDT
    CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announc...
    READ ARTICLE
  3. Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

    GlobeNewswire MAR 24, 2025 7:30 AM EDT
    Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to mode...
    READ ARTICLE
  4. Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

    GlobeNewswire MAR 11, 2025 7:30 AM EDT
    Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared ...
    READ ARTICLE
  5. The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

    PR Newswire FEB 28, 2025 8:23 AM EST
    The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanema...
    READ ARTICLE
  6. Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

    GlobeNewswire FEB 18, 2025 8:00 AM EST
    Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen ...
    READ ARTICLE
  7. Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

    Business Wire FEB 18, 2025 8:00 AM EST
    Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen ...
    READ ARTICLE
  8. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

    GlobeNewswire JAN 31, 2025 6:30 AM EST
    TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Toky...
    READ ARTICLE
  9. FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

    GlobeNewswire JAN 26, 2025 6:33 PM EST
    Once every four weeks maintenance dosing may be easier for patients and care partners to continue...
    READ ARTICLE
  10. FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

    PR Newswire JAN 26, 2025 6:30 PM EST
    FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzh...
    READ ARTICLE

Upcoming Events

Get notified of Biogen Inc.’s latest announcements, news, and event dates.
  • Upcoming earnings announcement (Unconfirmed)

    Jul 31, 2025
  • Upcoming dividend payout

    Not Available
  • Upcoming stock splits

    Not Available